StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

Analysts at StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report issued to clients and investors on Friday. The firm set a “hold” rating on the stock.

A number of other research firms have also recently commented on EKSO. Lake Street Capital reduced their price target on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Ekso Bionics in a research report on Tuesday, March 4th.

Ekso Bionics Stock Down 9.7 %

Shares of Ekso Bionics stock opened at $0.38 on Friday. The stock’s 50-day moving average is $0.50 and its 200 day moving average is $0.71. Ekso Bionics has a one year low of $0.34 and a one year high of $1.53. The firm has a market cap of $9.38 million, a price-to-earnings ratio of -0.58 and a beta of 1.33. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). The business had revenue of $5.09 million for the quarter, compared to the consensus estimate of $5.05 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. Equities research analysts anticipate that Ekso Bionics will post -0.48 EPS for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.